Patent · US Active

HIV vaccine formulation

US10273268B2 · kind B2 · utility

1Cited by
12References
24Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 15, 2017
Grant dateApr 30, 2019
Priority date—
Expiry dateJun 15, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2740/16134
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.